Evidence map›Paper›PMID 32174215›Full record

ReviewExpert opinion on therapeutic targets2020

Sirtuins: potential therapeutic targets for regulating acute inflammatory response?

Vidula Vachharajani, Charles E McCall

Open access · greenAbstract readReview
In one paragraph

Review in Expert opinion on therapeutic targets, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 31 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. The Role of SIRT1 in Leukemia.Current treatment options in oncology · 2024
    Review
  8. Article
  9. Article
  10. Article
  11. Role of SIRT1 in Chemoresistant Leukemia.International journal of molecular sciences · 2023
    Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Potential of natural astaxanthin in alleviating the risk of cytokine storm in COVID-19.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Vidula VachharajaniDepartment of Critical Care Medicine/ Respiratory Institute; Inflammation and Immunity/ Lerner Research Institute, Cleveland Clinic Lerner College of Medicine, Cleveland, OH, USA.
Charles E McCallMolecular Medicine/ Department of Medicine, Wake Forest School of Medicine, Winston-Salem, NC, USA.
Cleveland Clinic Lerner College of Medicine · USWake Forest University · US

Funding

Bioenergetic and Epigenetic Reprogramming by Obesity in SepsisR01GM099807 · NIGMS · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI VACHHARAJANI, VIDULA · 2012 to 2020
$3.1M
NIGMS NIH HHS R01 GM099807
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Molecular Targeted TherapyAcute DiseaseAnimalsHomeostasisHumansInflammationNADSirtuinsNADSirtuinsAcute Inflammationacute Lung Injuryhemorrhagic shocksepsisseptic shocksirtuinsirtuins

Identifiers

PMID32174215
PMCPMC10514892
OpenAlexW3011659105

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.